Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...
Fidelity Diversified International Fund is a broadly diversified international equity strategy that seeks capital growth by ...
Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...
Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
The European Commission is seeking feedback from industry players about Novo Holdings' $16.5 billion proposed acquisition of ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback